<DOC>
	<DOCNO>NCT00220376</DOCNO>
	<brief_summary>This trial provide long-term data safety , satisfaction maintenance therapy fesoterodine ( SPM 907 ) subject overactive bladder syndrome . Subjects complete 12 week treatment period SP584 opportunity participate eligibility confirm . They receive fesoterodine 8mg option reduce dose 4mg scheduled visit , increase 8mg , procedure follow annual basis . The primary variable long-term safety tolerability , measure observation assessment adverse event duration therapy . Further safety variable include assessment laboratory parameter , change ECG , physical exam measurement residual urine . Secondary efficacy variable include various parameter derive micturition diary evaluation Quality Life questionnaire</brief_summary>
	<brief_title>Long-Term Open-Label Extension Trial Subjects Completing Phase 3 Trial Fesoterodine ( SP584 ) Treatment Overactive Bladder Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Overactive Bladder Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>